These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 36551630)

  • 1. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.
    Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
    Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
    Cancer Biol Med; 2024 May; 21(6):451-72. PubMed ID: 38801082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
    Jo W; Won T; Daoud A; Čiháková D
    Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
    Kreidieh FY; Tawbi HA
    Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
    Lee JB; Ha SJ; Kim HR
    Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
    Wang L; Bai L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
    Cai L; Li Y; Tan J; Xu L; Li Y
    J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer natural products targeting immune checkpoint protein network.
    Chun KS; Kim DH; Raut PK; Surh YJ
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
    Yadav R; Hakobyan N; Wang JC
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TIGIT therapies for solid tumors: a systematic review.
    Rousseau A; Parisi C; Barlesi F
    ESMO Open; 2023 Apr; 8(2):101184. PubMed ID: 36933320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
    Yeo J; Ko M; Lee DH; Park Y; Jin HS
    Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
    Rotte A; Jin JY; Lemaire V
    Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Next generation of anti-immune checkpoints antibodies].
    Bonnefoy N; Olive D; Vanhove B
    Med Sci (Paris); 2019 Dec; 35(12):966-974. PubMed ID: 31903901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
    Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
    Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.